Clozapine Monitoring in the Post-REMS World
While the abolition of REMS for clozapine expands access, the change could create confusion. Among the most relevant examples are mismatches between FDA recommendations for lifetime monitoring and the literature suggesting relaxation in monitoring after the period of highest neutropenia risk. The authors provide practical considerations for addressing this issue.
Authors
- José M. Rubio (ORCID: https://orcid.org/0000-0002-0056-4135)
- Jonathan M. Meyer (ORCID: https://orcid.org/0000-0001-7294-4834)
Institutions
- Northwell Health (US)
- University of California San Diego (US)
- Zucker Hillside Hospital (US)
Publication Details
- Journal
- The Journal of Clinical Psychiatry
- Published
- 2025-05-05
- DOI
- https://doi.org/10.4088/jcp.25ac15898
- Citations
- 5
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.36